EMA Grants PRIME Designation to CTX001, a Sickle Cell Disease Treatment
source: pixabay.com

EMA Grants PRIME Designation to CTX001, a Sickle Cell Disease Treatment

CRISPR Therapeutics, in combination with Vertex Pharmaceuticals, has recently announced that the European Medicines Agency (EMA) has granted the Priority Medicines (PRIME) designation for their sickle cell disease (SCD) treatment,…

Continue Reading EMA Grants PRIME Designation to CTX001, a Sickle Cell Disease Treatment
Experimental Compound Shows Benefit in Mouse Model of Charcot-Marie-Tooth Disease Type 1A
source: pixabay.com

Experimental Compound Shows Benefit in Mouse Model of Charcot-Marie-Tooth Disease Type 1A

According to a story from Charcot-Marie-Tooth News, an experimental HDAC6 inhibitor called CKD-504 appeared to restore myelination in mouse and cell models of Charcot-Marie-Tooth disease type 1A in a recent…

Continue Reading Experimental Compound Shows Benefit in Mouse Model of Charcot-Marie-Tooth Disease Type 1A
Patients Receive First Dosing of Experimental Drug Targeting Neurodegenerative Diseases
source: pixabay.com

Patients Receive First Dosing of Experimental Drug Targeting Neurodegenerative Diseases

  According to a recent article in Business Wire, it is estimated that five million people in the United States over the age of sixty-five are coping with Alzheimer’s at…

Continue Reading Patients Receive First Dosing of Experimental Drug Targeting Neurodegenerative Diseases
Belimumab is the Second Drug to be Developed for Lupus in Over Fifty Years
source: pixabay.com

Belimumab is the Second Drug to be Developed for Lupus in Over Fifty Years

  Dr. Richard Furie at New York’s Feinstein Institutes recently interviewed with MedPage Today. Dr. Furie discussed the prognosis for lupus nephritis and belimumab (Benlysta), a recently-tested drug that appears…

Continue Reading Belimumab is the Second Drug to be Developed for Lupus in Over Fifty Years
Dr. Naveen Pemmaraju Discusses Myelofibrosis, MPNs, and Therapeutic Advancements
source: pixabay.com

Dr. Naveen Pemmaraju Discusses Myelofibrosis, MPNs, and Therapeutic Advancements

  This year, thanks to COVID-19, many conferences have been held online. These play a crucial role in spreading data, facilitating conversations, and determining potential treatment options for patients with…

Continue Reading Dr. Naveen Pemmaraju Discusses Myelofibrosis, MPNs, and Therapeutic Advancements
Living with Graves’ Disease? Then be on the Lookout for Thyroid Eye Disease
source: pixabay.com

Living with Graves’ Disease? Then be on the Lookout for Thyroid Eye Disease

Graves' Disease Awareness Month is recognized in July of each year. As part of this year's awareness campaign, the nonprofit organization Prevent Blindness and Horizon Therapeutics collaborated to create the…

Continue Reading Living with Graves’ Disease? Then be on the Lookout for Thyroid Eye Disease
Rare Classroom: CASQ2-Related Catecholaminergic Polymorphic Ventricular Tachycardia
source: shutterstock

Rare Classroom: CASQ2-Related Catecholaminergic Polymorphic Ventricular Tachycardia

Welcome to the Rare Classroom, a new series from Patient Worthy. Rare Classroom is designed for the curious reader who wants to get informed on some of the rarest, most…

Continue Reading Rare Classroom: CASQ2-Related Catecholaminergic Polymorphic Ventricular Tachycardia
Phase 3 Clinical Data on Vosorotide for Achondroplasia Presented at ASBMR Annual Meeting
source: pixabay.com

Phase 3 Clinical Data on Vosorotide for Achondroplasia Presented at ASBMR Annual Meeting

Last week, biotechnology company BioMarin announced that Dr. Lynda Polgreen, MD, MS would present at the American Society for Bone and Mineral Research (ASBMR) Annual 2020 Meeting. Her presentation centered…

Continue Reading Phase 3 Clinical Data on Vosorotide for Achondroplasia Presented at ASBMR Annual Meeting
Myotonic Dystrophy Type 1: RNA-Targeted CRISPR Shows Promise in Mouse Model
source: pixabay.com

Myotonic Dystrophy Type 1: RNA-Targeted CRISPR Shows Promise in Mouse Model

According to a story from PR Newswire, the RNA-targeted gene therapy company Locanabio, Inc. has recently released findings from a preclinical evaluation of an RNA-targeted CRISPR Cas9 (RCas9) system as…

Continue Reading Myotonic Dystrophy Type 1: RNA-Targeted CRISPR Shows Promise in Mouse Model
Pegcetacoplan for Paroxysmal Nocturnal Hemoglobinuria: Marketing Applications Submitted
source: pixabay.com

Pegcetacoplan for Paroxysmal Nocturnal Hemoglobinuria: Marketing Applications Submitted

  Recently, biopharmaceutical company Apellis Pharmaceuticals announced submission of a New Drug Application (NDA) and Marketing Authorization Application (MAA) for pegcetacoplan. If approved, these applications will allow for patients with…

Continue Reading Pegcetacoplan for Paroxysmal Nocturnal Hemoglobinuria: Marketing Applications Submitted